Top sci­en­tists and BD ex­ecs craft Cul­li­nan, a $150 mil­lion R&D port­fo­lio shop fo­cused on can­cer

Close to six years ago, then Am­gen R&D chief Roger Perl­mut­ter told me he had been “car­ry­ing a torch for (CSO) Patrick Baeuer­le at Mi­cromet for a long time.” That ad­mi­ra­tion ex­plains why Perl­mut­ter was will­ing to pay more than a bil­lion dol­lars to buy Mi­cromet — where Baeuer­le was R&D chief — which even­tu­al­ly de­liv­ered the pi­o­neer­ing Blin­cy­to to the mar­ket.

Af­ter a stint at Am­gen, biotech be­ing the kind of project-fo­cused in­dus­try it’s be­come, Baeuer­le be­came a VC at MPM and a start­up mae­stro. And to­day he’s hav­ing a com­ing out par­ty for Cul­li­nan On­col­o­gy, an in­tense­ly project-ori­ent­ed biotech bankrolled with $150 mil­lion to set up a port­fo­lio of can­cer drugs to de­vel­op.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER